Approval · Notice of Compliance 16217 · 2014
FLUZONE QUADRIVALENT: Notice of Compliance 16217
Issued October 17, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16217
- Date
- October 17, 2014
- Company
- Sanofi Pasteur LimitedSwiftwater, Pennsylvania, United States
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New presentation - multidose vial
- Therapeutic class
- Active immunizing agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| FLUZONE QUADRIVALENT | 02432730 | Dormant |
Medicinal ingredients
- HAEMAGGLUTININ-STRAIN A(H1N1) 30 MCG per ML
- HAEMAGGLUTININ-STRAIN A(H3N2) 30 MCG per ML
- HAEMAGGLUTININ-STRAIN B(VICTORIA) 30 MCG per ML
- HAEMAGGLUTININ-STRAIN B(YAMAGATA) 30 MCG per ML